Related Experiment Video
Updated: Jan 3, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary hypertension in pediatrics. A feasible approach to bridge the gap between real world and guidelines
Giuseppe Calcaterra1, Pier Paolo Bassareo2, Francesco Barilla3
1Department of Cardiology, University of Palermo, Palermo, Italy.
Insights
Pediatric pulmonary hypertension (PH) requires simplified classification. A new 5-group method aids clinicians in diagnosing this severe condition, improving patient outcomes.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Neonatology
Background:
- Pediatric pulmonary hypertension (PH) is rare but severe, with distinct causes from adults.
- Existing PH classifications for adults are inadequate for children.
- Previous pediatric classifications are complex and difficult for clinicians to apply.
Purpose of the Study:
- To propose a simplified clinical classification for pediatric pulmonary hypertension.
- To aid clinicians in the initial diagnosis and management of pediatric PH.
- To improve understanding and recognition of PH in neonates and children.
Main Methods:
- Review of existing adult and pediatric PH classification systems.
- Analysis of the unique etiologies of PH in pediatric populations.
- Development of a simplified 5-group clinical classification based on physician specialty.
Main Results:
- Existing classifications are complex and not easily understood by clinicians.
- A new, simplified 5-group classification is proposed: neonatal, cardiac, developmental, idiopathic, and syndromic PH.
- This simplified approach is intended to assist physicians in initial diagnosis.
Conclusions:
- Pediatric PH is a serious condition with high morbidity and mortality if untreated.
- A simplified classification aids clinicians, including neonatologists, pediatric cardiologists, and pulmonologists.
- The proposed classification complements, rather than replaces, existing systems for better clinical utility.
Abstract:
Pulmonary hypertension (PH) is quite infrequent in pediatric age and its most common etiologies include idiopathic pulmonary arterial hypertension, PH related to congenital heart diseases, bronchopulmonary dysplasia (chronic lung disease), persistence of pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. The developed for adult patients PH classification shows limitations when applied to pediatric subjects since the underlying causes are markedly different between the two ages. In 2011, the Pulmonary Vascular Research Institute Panama Task Force outlined the first specific pediatric pulmonary hypertensive vascular disease diagnostic classification, including 10 main categories and 109 subcategories, thus testifying PH complex pathophysiology during newborns/children growth and development. The unique, distinctive features of pediatric PH were recognized also during the fifth World Symposium on pulmonary hypertension in 2013 and then confirmed in the recent 2018 sixth World Symposium. For the sake of uniformity, an attempt to adapt the adult classification to pediatric patients was made. However, all these commendable classifications are very complex and maybe not of quick comprehension for clinicians. A clinical simpler and simplified method is now suggested, comprising only five groups: neonatal, cardiac, developmental, idiopathic, and syndromic PH. This approach is not aimed at replacing the already existing classifications but is mainly based on the kind of specialized physician (neonatologist, pediatric cardiologist, pediatrician, pulmonologist, general practitioner) who first faces and looks after the child with suspected PH. What is dramatically known is that pediatric PH is a severe disease which, when untreated or undertreated, may lead to increased morbidity and mortality.
More Related Videos
10:03Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...